Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Merck Millipore Introduces Magna™ Nuclear RIP Kits

Published: Tuesday, August 05, 2014
Last Updated: Tuesday, August 05, 2014
Bookmark and Share
Facilitates isolation and analysis of RNA molecules associated with chromatin.

Merck Millipore has introduced the Magna™ Nuclear RNA-binding Protein Immunoprecipitation (RIP) kits. These kits are specially designed to allow the discovery and analysis of both coding and non-coding chromatin-associated RNAs.

Two versions of the kit are available, enabling users to analyze RNA both strongly and weakly associated with chromatin; one version uses cross-linked chromatin while the other uses native chromatin.

Native RIP allows recovery of high affinity, more direct interactions while the cross-linked method is designed to capture higher molecular weight complexes and more readily trap weaker interacting RNAs.

Compared with other kits available to researchers, the Magna™ Nuclear RIP kits deliver much lower background signals, high signal-to-noise ratios and have been demonstrated to work in RNA-seq to enable NGS-based discovery and profiling. The kits offer flexible and scalable input requirements; RNA can be recovered from as few as 5,000 cells (cross-linked) or 100,000 cells (native).

"A significant amount of research is being invested in understanding the complex nature of how various chromatin-associated RNAs impact gene expression and epigenetic regulation," said Christophe Couturier, Senior Vice President and Head of the Merck Millipore Bioscience Business Area. "With the Magna™ Nuclear RIP kits, researchers now have complete, user-friendly kits to facilitate isolation and identification of regulatory RNAs such as short and long non-coding RNAs, snRNAs and enhancer RNAs."

These new kits add to the family of Magna™ RIP kits first introduced in 2009, which allowed for analysis of cytoplasmic and nuclear-associated RNA molecules.

With the new Magna™ Nuclear RIP kits, researchers can target those proteins associated with RNA in a chromatin context.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Merck Millipore Opens New R&D Center
Facility fosters company's focus on Bioavailability Enhancement.
Monday, July 15, 2013
Scientific News
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
RNA-Based Drugs Give More Control Over Gene Editing
CRISPR/Cas9 gene editing technique can be transiently activated and inactivated using RNA-based drugs, giving researchers more precise control in correcting and inactivating genes.
University of Glasgow Researchers Make An Impact in 60 Seconds
Early-career researchers were invited to submit an engaging, dynamic and compelling 60 second video illuminating an aspect of their research.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
Dead Bacteria to Kill Colorectal Cancer
Scientists from Nanyang Technological University (NTU Singapore) have successfully used dead bacteria to kill colorectal cancer cells.
CRISPR-Cas9 Gene Editing: Check Three Times, Cut Once
Two new studies from UC Berkeley should give scientists who use CRISPR-Cas9 for genome engineering greater confidence that they won’t inadvertently edit the wrong DNA.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos